ProMIS Neurosciences (PMN) Cash from Investing Activities (2021 - 2022)
ProMIS Neurosciences' (PMN) quarterly Cash from Investing Activities came in at $43.0 in Q4 2022, down 99.96% YoY from $95805.0 in Q4 2021, and up 79.17% on a QoQ basis from $24.0 in Q3 2022.
ProMIS Neurosciences (PMN) Cash from Investing Activities (2021 - 2022) Analysis & Trends
ProMIS Neurosciences (PMN) has 2 years of Cash from Investing Activities data on file, last reported at $43.0 in Q4 2022.
- Quarterly Cash from Investing Activities fell 99.96% year-over-year to $43.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was -$1981.0 (changed N/A YoY) and the FY2025 annual result came in at -$702.0, down 1.3% from the prior year.
- Cash from Investing Activities improved to $43.0 in Q4 2022, from $24.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $95805.0 in Q4 2021 to a low of -$3559.0 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | ProMIS Neurosciences | 132.34 Mn | 78.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 43.00 |
| Dec 31, 2022 | 43.00 |
| Sep 30, 2022 | 24.00 |
| Sep 30, 2022 | 24.00 |
| Jun 30, 2022 | 9.00 |
| Jun 30, 2022 | 9.00 |
| Mar 31, 2022 | -2,057.00 |
| Mar 31, 2022 | -2,057.00 |
| Dec 31, 2021 | 95,805.00 |
| Dec 31, 2021 | 95,805.00 |
| Sep 30, 2021 | -3,559.00 |
| Sep 30, 2021 | -3,559.00 |